What You Should Know:
- Today, OM1 announced the launch of its Parkinson’s Disease datasets, enhancing its Mental Health & Neuroscience Real-World Data Network.
- OM1’s Mental Health & Neuroscience Real-World Data Network, which already includes robust datasets focused on Major Depressive Disorder, Multiple Sclerosis, Bipolar Disorder I and Schizophrenia, will further expand to include Alzheimer’s Disease in the coming months.
Parkinson’s Disease Premium Dataset
Nearly 1 million Americans are living with Parkinson’s Disease, but there’s currently no known cure and no interventions that help stop the progression of the disease. Understanding treatment options & disease progression in patients is critical in the next steps of care. The Parkinson’s Disease dataset includes more than 7,000 patients prospectively followed by neurologists in hundreds of clinics across all 50 states. To enrich the data, OM1 extracts relevant information from treating clinician notes using its unique artificial intelligence (AI) and language modeling capabilities. Data points include key symptoms, disease severity, treatments, longitudinal outcomes, and clinical response. In addition to the premium dataset, data from an additional 700,000 PD patients are available in the OM1 Real-World Data Cloud™ for modeling health economics outcomes, patient recruitment for clinical trials, prescriber trends, and other research needs.
The dataset combines real-world data sources, such as EMR, medical and pharmacy claims, mortality data and social determinants of health (SDoH), to provide deeper insights into Parkinson’s Disease patient journeys. The data can be leveraged to accelerate medical research and to support approvals and reimbursement, reducing the time to market and improving existing therapies.
“Understanding treatments and disease progression in patients suffering from this devastating illness with real-world data is critical for driving clinical advancements,” said Carl Marci, MD, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. “Among our goals is to break down barriers that impede access to deep clinical insights that otherwise would go unseen and unused to help develop personalized and targeted treatments for patients with Parkinson’s Disease.”
